Erasca (ERAS) News Today $1.40 -0.06 (-4.11%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 08/8/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Analysts Set Erasca, Inc. (NASDAQ:ERAS) Target Price at $4.57August 9 at 2:43 AM | americanbankingnews.comErasca (ERAS) to Release Quarterly Earnings on MondayAugust 9 at 2:57 AM | americanbankingnews.comErasca (ERAS) to Release Earnings on MondayAugust 5, 2025 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Receives Consensus Rating of "Buy" from BrokeragesAugust 4, 2025 | marketbeat.comErasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid TumorsAugust 1, 2025 | msn.comErasca, Inc. (NASDAQ:ERAS) Given Consensus Rating of "Buy" by AnalystsJuly 10, 2025 | marketbeat.comUSA News Group: Oncology Innovation Just Hit a Turning Point -- Here's What to WatchJune 30, 2025 | finanznachrichten.deErasca, Inc. (NASDAQ:ERAS) Given Consensus Recommendation of "Buy" by BrokeragesJune 15, 2025 | marketbeat.comWellington Management Group LLP Takes Position in Erasca, Inc. (NASDAQ:ERAS)June 7, 2025 | marketbeat.comFDA clears Erasca’s new cancer drug applicationsJune 3, 2025 | uk.investing.comErasca Announces Clearance Of IND Application By FDA For ERAS-4001June 3, 2025 | nasdaq.comErasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001June 2, 2025 | globenewswire.comTwo Sigma Investments LP Has $2.41 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 198,600 Shares of Erasca, Inc. (NASDAQ:ERAS)June 1, 2025 | marketbeat.comBank of America Corp DE Has $4.88 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS)May 30, 2025 | marketbeat.comErasca to Present at Upcoming Investor Conferences in JuneMay 29, 2025 | globenewswire.comErasca, Inc. (NASDAQ:ERAS) Shares Sold by Janus Henderson Group PLCMay 27, 2025 | marketbeat.comMillennium Management LLC Increases Position in Erasca, Inc. (NASDAQ:ERAS)May 26, 2025 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Buy" by AnalystsMay 23, 2025 | marketbeat.comSuvretta Capital Management LLC Has $30.91 Million Stock Position in Erasca, Inc. (NASDAQ:ERAS)May 19, 2025 | marketbeat.comProsight Management LP Trims Holdings in Erasca, Inc. (NASDAQ:ERAS)May 17, 2025 | marketbeat.com5,136,795 Shares in Erasca, Inc. (NASDAQ:ERAS) Bought by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Position in Erasca, Inc. (NASDAQ:ERAS)May 15, 2025 | marketbeat.comErasca Reports First Quarter 2025 Business Updates and Financial ResultsMay 13, 2025 | globenewswire.comErasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash RunwayMay 13, 2025 | globenewswire.comErasca (ERAS) to Release Earnings on WednesdayMay 9, 2025 | marketbeat.comErasca to Present at the Bank of America Securities Health Care ConferenceMay 7, 2025 | globenewswire.comErasca (NASDAQ:ERAS) Earns "Buy" Rating from HC WainwrightMay 2, 2025 | marketbeat.comErasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual MeetingApril 29, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Erasca (ERAS)April 29, 2025 | theglobeandmail.comErasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Buy" from BrokeragesApril 28, 2025 | marketbeat.comMarshall Wace LLP Sells 1,000,700 Shares of Erasca, Inc. (NASDAQ:ERAS)April 27, 2025 | marketbeat.comWalleye Capital LLC Has $348,000 Stock Position in Erasca, Inc. (NASDAQ:ERAS)April 27, 2025 | marketbeat.comErasca, Inc.: Carving A Different Niche In RAS SignalingApril 25, 2025 | seekingalpha.comErasca, Inc.: Carving A Different Niche In RAS SignalingApril 25, 2025 | seekingalpha.comSilverarc Capital Management LLC Grows Stock Holdings in Erasca, Inc. (NASDAQ:ERAS)April 24, 2025 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Short Interest Down 17.8% in MarchApril 22, 2025 | marketbeat.comJPMorgan Chase & Co. Lowers Holdings in Erasca, Inc. (NASDAQ:ERAS)April 22, 2025 | marketbeat.comIs Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 17, 2025 | msn.comWellington Management Group LLP Acquires New Stake in Erasca, Inc. (NASDAQ:ERAS)April 15, 2025 | marketbeat.comVanguard Group Inc. Sells 614,840 Shares of Erasca, Inc. (NASDAQ:ERAS)April 15, 2025 | marketbeat.comErasca Slides As Insider Purchases Lose Another US$84kApril 8, 2025 | finance.yahoo.comErasca, Inc. (NASDAQ:ERAS) Receives Consensus Recommendation of "Buy" from AnalystsApril 2, 2025 | marketbeat.comIPG Investment Advisors LLC Acquires Shares of 169,978 Erasca, Inc. (NASDAQ:ERAS)March 31, 2025 | marketbeat.comErasca (ERAS) Gets a Buy from J.P. MorganMarch 30, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Erasca (ERAS)March 27, 2025 | markets.businessinsider.comErasca (NASDAQ:ERAS) Now Covered by Raymond JamesMarch 27, 2025 | marketbeat.comRaymond James Initiates Coverage of Erasca (ERAS) with Outperform RecommendationMarch 26, 2025 | msn.comErasca Announces Three Poster Presentations at the 2025 AACR Annual MeetingMarch 25, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for Erasca FY2029 Earnings?March 24, 2025 | marketbeat.com Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Media Mentions By Week ERAS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERAS News Sentiment▼0.340.50▲Average Medical News Sentiment ERAS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERAS Articles This Week▼42▲ERAS Articles Average Week Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ocular Therapeutix News Kiniksa Pharmaceuticals International News Apogee Therapeutics News Arcutis Biotherapeutics News Immunocore News ARS Pharmaceuticals News Tarsus Pharmaceuticals News Adaptive Biotechnologies News Schrodinger News Janux Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERAS) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
